[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @GilaMonstrum Noumena Analysis Noumena Analysis posts on X about $gpcr, $lly the most. They currently have XXXXX followers and X posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::1494036559502401539/interactions)  - X Week XXXXX -XX% - X Month XXXXXX -XX% - X Months XXXXXXX -XX% - X Year XXXXXXX +59% ### Mentions: X [#](/creator/twitter::1494036559502401539/posts_active)  - X Week X -XX% - X Month XX -XXXX% - X Months XXX +22% - X Year XXX +58% ### Followers: XXXXX [#](/creator/twitter::1494036559502401539/followers)  - X Week XXXXX +0.66% - X Month XXXXX +6.70% - X Months XXXXX +52% - X Year XXXXX +104% ### CreatorRank: undefined [#](/creator/twitter::1494036559502401539/influencer_rank)  ### Social Influence **Social category influence** [stocks](/list/stocks) XXXXX% **Social topic influence** [$gpcr](/topic/$gpcr) 33.33%, [$lly](/topic/$lly) XXXXX% **Top accounts mentioned or mentioned by** [@bioinvestor24](/creator/undefined) [@researchpulse1](/creator/undefined) [@cyrpto2021](/creator/undefined) **Top assets mentioned** [Eli Lilly and Company (LLY)](/topic/$lly) ### Top Social Posts Top posts by engagements in the last XX hours "Based on my PK/PD model I expect $GPCR to underperform in both ACCESS and ACCESS X especially with $LLY orforglipron P3 as the benchmark. Orforglipron has a longer T1/2 (approx. XX hours) and a later Tmax (7.4 hours) compared with aleniglipron (T1/2 approx. XXX hours Tmax XXX hours). This leads to meaningful differences in their PK profiles (slide X for aleni slide X for orfo): aleni produces larger plasma concentration fluctuations and higher peak-to-trough ratios (slide 3) which likely translates into a worse safety profile than orforgliprons despite similar titration schemes. Using" [X Link](https://x.com/GilaMonstrum/status/1990501478830612915) 2025-11-17T19:25Z 2122 followers, 24.3K engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@GilaMonstrum Noumena Analysis
Noumena Analysis posts on X about $gpcr, $lly the most. They currently have XXXXX followers and X posts still getting attention that total XXXXX engagements in the last XX hours.
Engagements: XXXXX #
- X Week XXXXX -XX%
- X Month XXXXXX -XX%
- X Months XXXXXXX -XX%
- X Year XXXXXXX +59%
Mentions: X #
- X Week X -XX%
- X Month XX -XXXX%
- X Months XXX +22%
- X Year XXX +58%
Followers: XXXXX #
- X Week XXXXX +0.66%
- X Month XXXXX +6.70%
- X Months XXXXX +52%
- X Year XXXXX +104%
CreatorRank: undefined #
Social Influence
Social category influence stocks XXXXX%
Social topic influence $gpcr 33.33%, $lly XXXXX%
Top accounts mentioned or mentioned by @bioinvestor24 @researchpulse1 @cyrpto2021
Top assets mentioned Eli Lilly and Company (LLY)
Top Social Posts
Top posts by engagements in the last XX hours
"Based on my PK/PD model I expect $GPCR to underperform in both ACCESS and ACCESS X especially with $LLY orforglipron P3 as the benchmark. Orforglipron has a longer T1/2 (approx. XX hours) and a later Tmax (7.4 hours) compared with aleniglipron (T1/2 approx. XXX hours Tmax XXX hours). This leads to meaningful differences in their PK profiles (slide X for aleni slide X for orfo): aleni produces larger plasma concentration fluctuations and higher peak-to-trough ratios (slide 3) which likely translates into a worse safety profile than orforgliprons despite similar titration schemes. Using"
X Link 2025-11-17T19:25Z 2122 followers, 24.3K engagements